The presence of TERT mutation is a prognostic and predictive biomarker in patients with cancers such as central nervous system, bladder, thyroid, skin, etc., associated with tumor recurrence and survival. With its detection limit characteristics as low as 5% copies/rxn, the PNAClamp™ TERT mutation detection kit is the qualitative diagnostic test kit that is capable of detecting 2 different types of TERT promoter mutations from formalin-fixed kerosene embedded (FFPE) tissue, fresh tissue and biopsy tissues using peptide nucleic acid (PNA)-mediated real-time PCR-mediated peptide nucleic acid (PNA) clamping technology.